Novartis (NVS) Short Interest Ratio & Short Volume $114.23 -0.29 (-0.25%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$114.85 +0.62 (+0.54%) As of 07/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Novartis Short Interest DataNovartis (NVS) has a short interest of 4.06 million shares, representing 0.21% of the float (the number of shares available for trading by the public). This marks a 4.91% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.4, indicating that it would take 2.4 days of the average trading volume of 1.60 million shares to cover all short positions.Current Short Interest4,060,000 sharesPrevious Short Interest3,870,000 sharesChange Vs. Previous Month+4.91%Dollar Volume Sold Short$491.58 millionShort Interest Ratio2.4 Days to CoverLast Record DateJune 30, 2025Outstanding Shares2,112,420,000 sharesFloat Size1,900,000,000 sharesShort Percent of Float0.21%Today's Trading Volume2,546,533 sharesAverage Trading Volume1,602,884 sharesToday's Volume Vs. Average159% Short Selling Novartis? Sign up to receive the latest short interest report for Novartis and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNVS Short Interest Over TimeNVS Days to Cover Over TimeNVS Percentage of Float Shorted Over Time Novartis Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20254,060,000 shares $491.58 million +4.9%0.2%2.4 $121.08 6/15/20253,870,000 shares $461.85 million +15.9%0.2%2.1 $119.34 5/31/20253,340,000 shares $386.34 million -0.3%0.2%1.6 $115.67 5/15/20253,350,000 shares $363.04 million -27.2%0.2%1.4 $108.37 4/30/20254,600,000 shares $521.00 million +2.0%0.2%1.9 $113.26 4/15/20254,510,000 shares $495.38 million +39.6%0.2%1.8 $109.84 3/31/20253,230,000 shares $360.09 million -19.7%0.2%1.4 $111.48 3/15/20254,020,000 shares $438.77 million -20.2%0.2%2 $109.15 2/28/20255,040,000 shares $549.64 million +26.3%0.3%2.8 $109.06 2/15/20253,990,000 shares $420.66 million -2.2%0.2%2.4 $105.43 Get the Latest News and Ratings for NVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. 1/31/20254,080,000 shares $426.98 million -7.7%0.2%2.8 $104.65 1/15/20254,420,000 shares $437.80 million +9.1%0.2%3.4 $99.05 12/31/20244,050,000 shares $394.11 million -3.8%0.2%3.5 $97.31 12/15/20244,210,000 shares $414.10 million -6.2%0.2%3.7 $98.36 11/30/20244,490,000 shares $474.91 million -6.3%0.2%4 $105.77 11/15/20244,790,000 shares $493.66 million +0.6%0.2%4.2 $103.06 10/31/20244,760,000 shares $515.89 million -0.6%0.2%4.5 $108.38 10/15/20244,790,000 shares $556.79 million -16.0%0.2%4.7 $116.24 9/30/20245,700,000 shares $655.67 million +7.1%0.3%4.9 $115.03 9/15/20245,320,000 shares $615.31 million -6.7%0.3%4.4 $115.66 8/31/20245,700,000 shares $689.07 million -2.9%0.3%4.5 $120.89 8/15/20245,870,000 shares $665.25 million +4.6%0.3%4.5 $113.33 7/31/20245,610,000 shares $625.46 million -10.0%0.3%4.2 $111.49 7/15/20246,230,000 shares $687.36 million -0.2%0.3%4.2 $110.33 6/30/20246,240,000 shares $664.31 million -0.6%0.3%4.3 $106.46 6/15/20246,280,000 shares $663.92 million +60.2%0.3%4.1 $105.72 5/31/20243,920,000 shares $404.27 million -23.6%0.2%2.6 $103.13 5/15/20245,130,000 shares $529.52 million +21.6%0.3%3.3 $103.22 4/30/20244,220,000 shares $409.89 million +10.8%0.2%2.7 $97.13 4/15/20243,810,000 shares $359.66 million -9.5%0.2%2.4 $94.40 3/31/20244,210,000 shares $407.23 million +1.5%0.2%2.9 $96.73 3/15/20244,150,000 shares $403.71 million -8.4%0.2%3 $97.28 2/29/20244,530,000 shares $457.17 million +10.0%0.2%3.1 $100.92 2/15/20244,120,000 shares $410.39 million +5.9%0.2%2.8 $99.61 1/31/20243,890,000 shares $402.58 million -10.4%0.2%2.7 $103.49 1/15/20244,340,000 shares $466.33 million +15.1%0.2%2.8 $107.45 12/31/20233,770,000 shares $380.66 million +5.9%0.2%2.3 $100.97 12/15/20233,560,000 shares $346.74 million +4.7%0.2%2.2 $97.40 11/30/20233,400,000 shares $332.83 million -11.5%0.2%2.2 $97.89 11/15/20233,840,000 shares $360.19 million +5.2%0.2%2.6 $93.80The big winner of Crypto week? (Ad)It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bitcoin hitting $123,000 and giants like BlackRock and Fidelity pouring in, one expert believes a lesser-known coin could soon be vaulted to the top — possibly even landing in the government’s digital reserve.See the coin positioned to win from Washington’s crypto push 10/31/20233,650,000 shares $341.57 million +13.4%0.2%2.7 $93.58 10/15/20233,220,000 shares $313.11 million -19.1%0.2%2.6 $97.24 9/30/20233,980,000 shares $405.40 million +2.1%0.2%3.2 $101.86 9/15/20233,900,000 shares $400.26 million -2.5%0.2%3 $102.63 8/31/20234,000,000 shares $401.92 million +2.8%0.2%2.8 $100.48 8/15/20233,890,000 shares $399.08 million +2.6%0.2%2.2 $102.59 7/31/20233,790,000 shares $397.57 million +1.3%0.2%2 $104.90 7/15/20233,740,000 shares $369.62 million -2.6%0.2%1.9 $98.83 6/30/20233,840,000 shares $387.42 million -7.0%0.2%1.9 $100.89 6/15/20234,130,000 shares $418.70 million -5.7%0.2%2 $101.38 5/31/20234,380,000 shares $421.53 million +2.3%0.2%1.9 $96.24 5/15/20234,280,000 shares $441.35 million -10.5%0.2%2.1 $103.12 4/30/20234,780,000 shares $490.28 million -13.1%0.2%2.3 $102.57 4/15/20235,500,000 shares $538.34 million -13.1%0.3%2.5 $97.88 3/31/20236,330,000 shares $582.36 million No Change0.3%2.8 $92.00 3/15/20236,330,000 shares $519.69 million -4.1%0.3%3.1 $82.10 2/28/20236,600,000 shares $555.19 million +2.5%0.3%3.4 $84.12 2/15/20236,440,000 shares $561.44 million +16.9%0.3%3.3 $87.18 1/31/20235,510,000 shares $499.32 million +3.6%0.3%2.7 $90.62 1/15/20235,320,000 shares $484.44 million +11.1%0.2%2.6 $91.06 12/30/20224,790,000 shares $434.55 million -10.6%0.2%2.4 $90.72 12/15/20225,360,000 shares $487.17 million +1.3%0.2%2.5 $90.89 11/30/20225,290,000 shares $473.77 million +0.6%0.2%2.4 $89.56 11/15/20225,260,000 shares $440.95 million -14.1%0.2%2.1 $83.83 10/31/20226,120,000 shares $496.52 million +0.7%0.3%2.6 $81.13 10/15/20226,080,000 shares $459.47 million +6.3%0.3%2.6 $75.57 9/30/20225,720,000 shares $434.78 million +2.3%0.3%2.4 $76.01 9/15/20225,590,000 shares $451.34 million -1.2%0.3%2.6 $80.74 8/31/20225,660,000 shares $455.74 million -10.7%0.3%2.6 $80.52 8/15/20226,340,000 shares $541.31 million +4.1%0.3%3.2 $85.38 7/31/20226,090,000 shares $522.70 million +1.2%0.3%2.7 $85.83 7/15/20226,020,000 shares $509.53 million +0.5%N/A2.6 $84.64 6/30/20225,990,000 shares $506.33 million -4.0%N/A2.5 $84.53 6/15/20226,240,000 shares $507.69 million +4.5%N/A2.6 $81.36 5/31/20225,970,000 shares $542.91 million -15.7%0.3%2.4 $90.94 5/15/20227,080,000 shares $607.61 million +10.8%0.3%2.7 $85.82 4/30/20226,390,000 shares $562.51 million -2.6%0.3%2.4 $88.03 4/15/20226,560,000 shares $606.93 million +6.7%0.3%2.4 $92.52 3/31/20226,150,000 shares $539.66 million -2.2%0.3%2.3 $87.75 3/15/20226,290,000 shares $532.95 million +10.7%0.3%2.3 $84.73 2/28/20225,680,000 shares $496.77 million +4.0%0.3%2 $87.46 2/15/20225,460,000 shares $471.85 million -25.9%0.2%2 $86.42 1/31/20227,370,000 shares $640.53 million +12.7%0.3%2.9 $86.91 1/15/20226,540,000 shares $592.20 million -11.4%0.3%2.6 $90.55 12/31/20217,380,000 shares $645.53 million +39.0%0.3%3.1 $87.47 12/15/20215,310,000 shares $432.87 million -20.5%0.2%2.2 $81.52 11/30/20216,680,000 shares $532.40 million +8.6%0.3%3.1 $79.70 11/15/20216,150,000 shares $506.02 million +3.7%0.3%2.9 $82.28 10/29/20215,930,000 shares $490.77 million +8.2%0.3%2.8 $82.76 10/15/20215,480,000 shares $456.65 million -3.0%0.3%2.8 $83.33The big winner of Crypto week? (Ad)It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bitcoin hitting $123,000 and giants like BlackRock and Fidelity pouring in, one expert believes a lesser-known coin could soon be vaulted to the top — possibly even landing in the government’s digital reserve.See the coin positioned to win from Washington’s crypto push 9/30/20215,650,000 shares $462.06 million +0.9%0.3%2.9 $81.78 9/15/20215,600,000 shares $476.45 million +16.7%0.3%3.1 $85.08 8/31/20214,800,000 shares $443.47 million +4.1%0.2%2.8 $92.39 8/13/20214,610,000 shares $432.56 million +0.2%0.2%2.7 $93.83 7/30/20214,600,000 shares $424.99 million -19.6%0.2%2.7 $92.39 7/15/20215,720,000 shares $521.95 million -13.9%0.3%3.2 $91.25 6/30/20216,640,000 shares $605.83 million +0.5%0.3%3.7 $91.24 6/15/20216,610,000 shares $620.75 million +0.9%0.3%3.5 $93.91 5/28/20216,550,000 shares $578.89 million +3.3%0.3%3.5 $88.38 5/14/20216,340,000 shares $560.46 million +2.6%0.3%3.5 $88.40 4/30/20216,180,000 shares $531.67 million -11.2%0.3%3.3 $86.03 4/15/20216,960,000 shares $603.78 million +6.9%0.3%3.5 $86.75 3/31/20216,510,000 shares $566.50 million +0.3%0.3%3.2 $87.02 3/15/20216,490,000 shares $546.00 million -3.1%0.3%3.3 $84.13 2/26/20216,700,000 shares $580.96 million +29.1%0.3%3.4 $86.71 2/12/20215,190,000 shares $478.47 million -3.0%0.2%2.5 $92.19 1/29/20215,350,000 shares $496.69 million -16.1%0.2%2.6 $92.84 1/15/20216,380,000 shares $603.68 million +44.0%0.3%3.1 $94.62 12/31/20204,430,000 shares $418.01 million +0.9%0.2%2.4 $94.36 12/15/20204,390,000 shares $397.51 million +10.6%0.2%2.3 $90.55 11/30/20203,970,000 shares $356.35 million +22.5%0.2%2.1 $89.76 11/15/20203,240,000 shares $278.96 million -23.0%0.2%1.7 $86.10 10/30/20204,210,000 shares $328.67 million +29.9%0.2%2.3 $78.07 10/15/20203,240,000 shares $283.27 million +39.7%0.2%1.9 $87.43 9/30/20202,320,000 shares $201.75 million -6.1%0.1%1.3 $86.96 9/15/20202,470,000 shares $224.77 million +14.9%0.1%1.5 $91.00 8/31/20202,150,000 shares $185.03 million +3.4%0.1%1.3 $86.06 8/14/20202,080,000 shares $176.07 million +18.2%0.1%1.2 $84.65 7/31/20201,760,000 shares $144.57 million -12.0%0.1%1 $82.14 NVS Short Interest - Frequently Asked Questions What is Novartis' current short interest? Short interest is the volume of Novartis shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 4,060,000 shares of NVS short. 0.21% of Novartis' shares are currently sold short. Learn More on Novartis' current short interest. What is a good short interest ratio for Novartis? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NVS shares currently have a short interest ratio of 2.0. Learn More on Novartis's short interest ratio. Which institutional investors are shorting Novartis? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Novartis: Quaker Wealth Management LLC, Jane Street Group LLC, Millennium Management LLC, ADAR1 Capital Management LLC, DRW Securities LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Capital Fund Management S.A., and Arrowpoint Investment Partners Singapore Pte. Ltd.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Novartis? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.21% of Novartis' floating shares are currently sold short. Is Novartis' short interest increasing or decreasing? Novartis saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,060,000 shares, an increase of 4.9% from the previous total of 3,870,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Novartis' float size? Novartis currently has issued a total of 2,112,420,000 shares. Some of Novartis' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Novartis currently has a public float of 1,900,000,000 shares. How does Novartis' short interest compare to its competitors? 0.21% of Novartis' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Novartis: Novo Nordisk A/S (0.58%), AstraZeneca PLC (0.22%), Sanofi (0.18%), GSK PLC Sponsored ADR (0.92%), Takeda Pharmaceutical Co. (0.16%), argenex SE (3.31%), BioNTech SE Sponsored ADR (2.65%), Summit Therapeutics PLC (24.12%), Insmed, Inc. (5.33%), Teva Pharmaceutical Industries Ltd. (3.49%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Novartis stock? Short selling NVS is an investing strategy that aims to generate trading profit from Novartis as its price is falling. NVS shares are trading down $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Novartis? A short squeeze for Novartis occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NVS, which in turn drives the price of the stock up even further. How often is Novartis' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NVS, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Novo Nordisk A/S Short Interest AstraZeneca Short Interest Sanofi Short Interest GSK Short Interest Takeda Pharmaceutical Short Interest argenex Short Interest BioNTech Short Interest Summit Therapeutics Short Interest Insmed Short Interest Teva Pharmaceutical Industries Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:NVS) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
